Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
8 participants
INTERVENTIONAL
2018-11-22
2019-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects
NCT01374139
Safety And Efficacy Of Bosutinib
NCT02501330
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
NCT05363488
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
NCT02546375
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
NCT06297161
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be required to not swallow, rather to only swish the bosutinib containing liquid in their mouths for approximately 10 seconds, after which the liquid will be spat out. Each participant will record the sensory attributes at timed intervals of 0 (immediately after dosing), 5, 10 and 20 minutes after spitting using a Bosutinib Taste Assessment Questionnaire.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A- Bosutinib in water
200 Mg of bosutinib (50 mg capsule x4) in Water solution
200 Mg capsules of bosutinib in Water solution
200 mg (4X50) Capsules in water
B- bosutinib in sorbitol
200 Mg of bosutinib sorbitol base in water solution
bosunitib sorbitol
200 Mg of bosutinib sorbitol solution
C- - bosutinib mannitol
200 Mg of bosutinib powder mannitol base in water solution
Bosutinib Mannitol
Bosutinib mannitol solution
D - bosutinib in mannitol low sweet
200 Mg of bosutinib mannitol low sweet solution
bosutinib in mannitol low sweet
bosutinib in mannitol solution low sweet
E- - bosutinib in mannitol high sweet
200 Mg of bosutinib High % sweet mannitol solution
bosutinib in mannitol high sweet
bosutinib in mannitol high sweet
F- - bosutinib low flavour
Taste assessment of 200 Mg of bosutinib low % Flavour
bosutinib taste low flavour
bosutinib solution low flavour
G- bosutinib high flavour
Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
bosutinib high flavour
bosutinib solution high flavour
H- - bosutinib capsules in low sweet
Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
Bosutinib capsules in low sweet
bosutinib capsules in low sweet
I - bosutinib capsules high sweet
200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
bosutinib capsules high sweet
Bosutinib capsules high sweet
J- - bosutinib capsules low flavour
Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
bosutinib capsules low flavour
Bosutinib capsules low flavour
K - bosutinib capsules high flavour
Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
bosutinib capsules high flavour
bosutinib capsules in high flavour
L - bosutinib capsules applesauce
200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
bosutinib capsules in applesauce
Bosutinib capsules in applesauce
M - bosutinib capsules full fat yougurt
200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
Bosutinib capsules in yogurt
bosutinib capsules in yogurt
N - bosutinib capsules in water (retest)
200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
bosutinib capsules in water
sham comparator, bosutinb in water retest
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
200 Mg capsules of bosutinib in Water solution
200 mg (4X50) Capsules in water
bosunitib sorbitol
200 Mg of bosutinib sorbitol solution
Bosutinib Mannitol
Bosutinib mannitol solution
bosutinib in mannitol low sweet
bosutinib in mannitol solution low sweet
bosutinib in mannitol high sweet
bosutinib in mannitol high sweet
bosutinib taste low flavour
bosutinib solution low flavour
bosutinib high flavour
bosutinib solution high flavour
bosutinib capsules in applesauce
Bosutinib capsules in applesauce
Bosutinib capsules in yogurt
bosutinib capsules in yogurt
bosutinib capsules in water
sham comparator, bosutinb in water retest
Bosutinib capsules in low sweet
bosutinib capsules in low sweet
bosutinib capsules high sweet
Bosutinib capsules high sweet
bosutinib capsules low flavour
Bosutinib capsules low flavour
bosutinib capsules high flavour
bosutinib capsules in high flavour
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Female participants of non-childbearing potential and/or male participants able to father children must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD).
-Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.
Type of Participant and Disease Characteristics:
2. Male and female participants who are overtly healthy as determined by medical evaluation including a detailed medical history, limited physical examination, including blood pressure (BP) and pulse rate measurement, or clinical laboratory tests.
3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
Weight:
4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>45 kg (99 lbs).
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.
Exclusion Criteria
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
2. A history of hypersensitivity to the active compounds or to any inactive ingredients (excipients) contained in the formulations.
3. Participants with conditions that affect their ability to taste - ie, dysgeusia, respiratory infection, cold, etc.
4. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or hepatitis C antibody (HCVAb). As an exception, a positive hepatitis B surface antibody (HBsAb) as a result of participant vaccination is permissible.
5. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
Prior/Concomitant Therapy:
6. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the first dose of investigational product. (Refer to Section 6.5 for additional details).
Prior/Concurrent Clinical Study Experience:
7. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product used in this study (whichever is longer).
Diagnostic Assessments:
8. A positive urine drug test.
9. Use of tobacco-containing products.
10. Screening supine blood pressure (BP) 140 mm Hg (systolic) or 90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is 140 mm Hg (systolic) or 90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility.
11. Baseline 12 lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval \>450 msec, complete left bundle branch block \[LBBB\], signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree atrioventricular \[AV\] block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is \>450 msec, this interval should be rate corrected using the Fridericia method and the resulting QTcF should be used for decision making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level 1.5 × upper limit of normal (ULN);
* Total bilirubin level 1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ULN.
Other Exclusions:
13. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of consuming 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
14. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
15. Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
16. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
17. Male participants with partners currently pregnant; male participants able to father children who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product or longer based upon the compound's half-life characteristics.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Clinical Research Unit
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-002346-37
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
BCHILD TASTE
Identifier Type: OTHER
Identifier Source: secondary_id
B1871057
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.